On August 7, 2025, the U.S. Food and Drug Administration (FDA) announced FDA PreCheck, a new two-phase framework aimed at bolstering the domestic pharmaceutical supply chain by streamlining the regulatory process for U.S.-based drug manufacturing facilities. Notably, the announcement also included information regarding an upcoming public meeting about the PreCheck framework and opportunity to comment and
Latest Post
More Posts
On-shoring Pharmaceutical Manufacturing: Navigating Regulatory Obligations and Strategic Considerations
U.S. HHS Office of General Counsel Statement of Organization Suggests Potential Consolidation, Expansion of Authority
Life Sciences Companies See New Path Open for Challenging FDA Decisions
Subscribe: Subscribe via RSS
Blogs
Firm/Org